Señales en vivo de DSGN | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions...

Stats
Volumen de hoy	173 975
Volumen promedio	264 463
Capitalización de mercado	208.33M
EPS	$-0.310 ( 2024-03-19 )
Próxima fecha de ganancias	( $-0.270 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.88
ATR14	$0.00500 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-25	Schmid John P.	Buy	17 809	Common Stock
2024-03-22	Schmid John P.	Buy	9 156	Common Stock
2024-03-25	Berger Heather A.	Buy	1 300	Common Stock
2024-03-13	Kim Jae B.	Sell	0	Common Stock
2024-03-13	Kim Jae B.	Sell	315 000	Stock Option (right to buy)

INSIDER POWER
76.30
Last 96 transactions
Buy: 40 774 561 \| Sell: 39 424 073

Volumen Correlación

Largo: 0.08 (neutral)

Corto: -0.36 (neutral)

Signal:(64.929) Neutral

Design Therapeutics, Inc. Correlación

10 Correlaciones Más Positivas
DRNA	0.955
ICPT	0.95
TWLVU	0.945
GRNV	0.943
QFIN	0.94
SANG	0.939
DXPE	0.938
LFMDP	0.937
SIGA	0.933
MTSL	0.933

10 Correlaciones Más Negativas
AGFS	-0.948
SBNYP	-0.94
NECB	-0.94
BTTX	-0.939
ATAK	-0.939
LYTS	-0.937
PTMN	-0.934
TACT	-0.933
LWAC	-0.929
HOFT	-0.928

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Design Therapeutics, Inc. Correlación - Moneda/Commodity

0.44
( neutral )

-0.50
( neutral )

0.00
( neutral )

0.20
( neutral )

0.62
( weak )

Design Therapeutics, Inc. Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.00120

FY	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.00120

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-466 000 (0.00 %)
EPS:	$-1.050

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.644

Financial Reports:

No articles found.

Design Therapeutics, Inc.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.